We use breast cancer experimental metastasis models in order to dissect the complexity of the whole metastatic process, in particular at later stages of metastatic colonization when it is clinically manifested and more difficult to treat.
Immunotherapy has shown great clinical benefits in different cancer types, but not yet for breast cancer. We seek for the molecular configurations of the different breast cancer subtypes that can render breast cancer more sensitive to immune checkpoint blockade immunotherapy.
Breast cancer stem
We study specifically these highly aggressive poorly differentiated tumor cells within the tumor heterogeneity of breast cancer. Understanding their biology, we will be able to find specific therapies to target these slippery cells to conventional therapies used in breast cancer treatment
Epithelial to mesenchymal transition (EMT) and its reversion play important roles at different steps of metastasis. We decipher the dynamics of this plastic cellular process influenced by the changing tumor microenvironment conditions during cancer metastasis
It goes from the discovery of new fundamental biological knowledge to the generation of translational findings for the quick clinical application of novel therapies to STOP cancer metastasis.
It is the most common cancer type among women and the second cause of cancer mortality in females. Our social commitment is to reduce the fear and the pain caused by breast cancer among women by finding new promising therapeutic strategies.
Metastasis accounts for more than 90% of cancer-related deaths. Understanding how to stop dreadful stage will lead to the development of new treatments, which is an imperative clinical need.
Look deep into nature, and then you will understand everything better
― Albert Einstein
PÉREZ-NUÑEZ I, ROZALÉN C, PALOMEQUE JA, SANGRADOR I, DALMAU M, COMERMA L, HERNÁNDEZ-PRAT A, CASADEVALL D, MENENDEZ S, DAN LIU D, SHEN M, BERENGER J, RIUS RUIZ I, PEÑA R, MONTAÑÉS JC, ALBÀ MM, BONNIN S, PONOMARENKO J, R GOMIS R, CEJALVO JM, SERVITJA S, M MARZESE D, MOREY L, VOORWERK L, ARRIBAS J, BERMEJO B, KOK M, PUSZTAI L, KANG Y, ALBANELL J, CELIÀ-TERRASSA T*
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer.
CELIÀ-TERRASSA T*, JOLLY MK
Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Review in Cold Spring Harbor Perspectives in Medicine.
BREAST CANCER 5-YEAR SURVIVAL RATE